Journal
EUROPEAN NEUROLOGY
Volume 50, Issue 1, Pages 10-15Publisher
KARGER
DOI: 10.1159/000070852
Keywords
myositis; dermatomyositis; polymyositis; tumor necrosis factor
Categories
Ask authors/readers for more resources
Tumor necrosis factor a neutralization seems a rational therapy for myositis because this proinflammatory cytokine has been implicated in the pathogenesis of this disorder. Until now, we have treated 2 patients with a chimeric anti-TNF-alpha monoclonal antibody (infliximab). Both patients demonstrated a marked and sustained subjective and objective improvement without the occurrence of any side effects. These preliminary results suggest that anti-TNF-alpha treatment with infliximab is a safe and rapidly effective therapy for myositis. Copyright (C) 2003 S. Karger AG, Basel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available